News

News: FDA approved Regeneron and Sanofi’s Praluent $REGN

Regeneron Pharmaceuticals, Inc. and Sanofi has announced that the U.S. Food and Drug Administration (FDA) approved Praluent® (alirocumab) Injection, the first FDAapproved treatment in a new class of drugs known as PCSK9 (proprotein convertase subtilisin/kexin type 9) inhibitors. Praluent is indicated as an adjunct to diet and maximally tolerated statin therapy for the treatment of

News: FDA approved Regeneron and Sanofi’s Praluent $REGN Read More »

News: Technicolor Acquires Cisco’s Division $CSCO

Technicolor announced it has entered into an exclusive agreement with Cisco to acquire our service provider video customer premises equipment (CPE) business for $600 million (or €550 million equivalent) in cash and stock. This transaction will bring together global leaders in networking, cloud, and the connected home to drive the future success of the service

News: Technicolor Acquires Cisco’s Division $CSCO Read More »

News: ZIOPHARM Drug Designated for Malignant Glioma $ZIOP

ZIOPHARM Oncology, Inc., a bio pharmaceutical company focused on the development and commercialization of new cancer therapies, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation for Ad-RTS-hIL-12 + veledimex in the treatment of patients with malignant Glioma. Ad-RTS-hIL-12 is a novel gene therapy candidate for the controlled expression

News: ZIOPHARM Drug Designated for Malignant Glioma $ZIOP Read More »